RT Journal Article
T1 The NUTRAOLEOUM Study, a randomized controlled trial, for achieving nutritional added value for olive oils.
A1 Biel, Sara
A1 Mesa, Maria-Dolores
A1 de la Torre, Rafael
A1 Espejo, Juan-Antonio
A1 Fernández-Navarro, Jose-Ramón
A1 Fitó, Montserrat
A1 Sánchez-Rodriguez, Estefanía
A1 Rosa, Carmen
A1 Marchal, Rosa
A1 Alche, Juan de Dios
A1 Expósito, Manuela
A1 Brenes, Manuel
A1 Gandul, Beatriz
A1 Calleja, Miguel Angel
A1 Covas, María-Isabel
K1 Functional olive oil
K1 Maslinic acid
K1 Oleanolic acid
K1 Olive oil
K1 Olive oil polyphenols
K1 Virgin olive oil
AB Virgin olive oil, a recognized healthy food, cannot be consumed in great quantities. We aim to assess in humans whether an optimized virgin olive oil with high phenolic content (OVOO, 429 mg/Kg) and a functional one (FOO), both rich in phenolic compounds (429 mg/Kg) and triterpenic acids (389 mg/kg), could provide health benefits additional to those supplied a by a standard virgin olive oil (VOO). A randomized, double-blind, crossover, controlled study will be conducted. Healthy volunteers (aged 20 to 50) will be randomized into one of three groups of daily raw olive oil consumption: VOO, OVOO, and FOO (30 mL/d). Olive oils will be administered over 3-week periods preceded by 2-week washout ones. The main outcomes will be markers of lipid and DNA oxidation, inflammation, and vascular damage. A bioavailability and dose-response study will be nested within this sustained- consumption one. It will be made up of 18 volunteers and be performed at two stages after a single dose of each olive oil. Endothelial function and nitric oxide will be assessed at baseline and at 4 h and 6 h after olive oil single dose ingestion. For the first time the NUTRAOLEUM Study will provide first level evidence on the health benefits in vivo in humans of olive oil triterpenes (oleanolic and maslinic acid) in addition to their bioavailability and disposition. The Trial has been registered in ClinicalTrials.gov ID: NCT02520739 .
YR 2016
FD 2016-10-22
LK http://hdl.handle.net/10668/10555
UL http://hdl.handle.net/10668/10555
LA en
DS RISalud
RD Apr 10, 2025